Myeloma

CURE Media Group Employee Part of 15-Person Team of Multiple Myeloma Patients and Supporters.

The CD38 monoclonal antibody Darzalex demonstrated a 31 percent overall response rate as monotherapy for patients with heavily pretreated multiple myeloma.

An all orally administered regimen containing Ninlaro, Revlimid and dexamethasone showed a 5.9-month improvement in progression-free survival compared with Revlimid and dexamethasone alone.

On January 16, a 15-person team of multiple myeloma patients, doctors, family members and supporters will climb the famed Uhuru Peak on Mount Kilimanjaro.

Blake A. Morrison discusses the recent excitement in myeloma research.

The addition of the PD-1 inhibitor Keytruda (pembrolizumab) to an established multiple myeloma regimen elicited responses in 76 percent of 17 patients with relapsed/refractory disease.

In updated data from a phase 3 study, the addition of Empliciti reduced the risk of progression or death by 27 percent.

Genetically engineered T cells eradicated multiple myeloma cells in a single patient with advanced disease.

The approval was based on data from the phase 3 ELOQUENT-2 trial, in which adding Empliciti to standard Revlimid (lenalidomide)/dexamethasone reduced the risk of disease progression by 30 percent.

Though clinical work is ongoing and early, researchers are already considering how to manage potentially fatal neurotoxicities in patients treated with chimeric antigen receptor (CAR) T-cell therapy.

The FDA has approved the oral medication Ninlaro in combination with Revlimid and dexamethasone for patients with multiple myeloma.

The approval was based on data from two open-label clinical trials.

Five years from now multiple myeloma will have a therapeutic backbone consisting entirely of combinations of novel agents, a leading myeloma researcher predicts.

C. Ola Landgren provides an overview of the diagnosis and treatment of smoldering multiple myeloma.

C. Ola Landgren discusses ways to measure response to treatment in multiple myeloma.